List of APIs/Active Pharmaceutical Ingredients Companies in Canada - 10

AcuPharma is a Canadian based company that provides a wide range of services for pharmaceutical and biotech partners. Our aim is to assist our clients in reaching their goals by providing chemistry expertise, as well as contract research and custom synthesis.

We are a Canada Based Contract Research Organization with expertise in contract research, custom synthesis, analytical services, and drug development. We support all your research needs by reducing the project timeline and cost.

Attix Pharmaceuticals designs and sellsactive pharmaceutical ingredients and ingredients for nutraceuticals, and food, for both human and veterinary applications.

Dalton is a contract pharmaceutical manufacturer which provides integrated chemistry, development, and manufacturing to biotechnology and pharmaceutical clients around the world. In its 42,000 sq. ft. facility, Dalton operates - cGMP manufacturing of Active Pharmaceutical Ingredients (APIs), - sterile injectables, - finished drug products in vials or syringes - solid oral dosage forms. APIs can be produced in gram to kilogram quantities, including sterile APIs. Dalton contract capabilities can support you at any stage of the regulatory process (Phase I, II, III, or commercial). Development services include - chemistry and process development, - medicinal chemistry, - custom drug conjugation, - targeted drug delivery systems, - analytical method development and validation, - ICH stability testing, - formulation, and - polymorphism screening. Dalton also supports the industry's pharmaceutical research programs with a catalog of 2,500 reference standards, building blocks, metabolites, and impurities with its Dalton Research Molecules division.

Juno Pharmaceuticals Canada sources, develops, and delivers life saving specialized pharmaceutical products for Canadian patients. Our colleagues work with trusted partners to co-develop novel drug delivery mechanisms that satisfy untapped market demand, first to market generic products, biosimilar offerings, and patent challenge strategies. Juno's portfolio consists of both branded and generic drug assets in multiple presentation forms including injectable drugs (vials, amps, & pre filled syringes), complex biosimilars, ophthalmic products, oral does tablets and capsules, prescription dermatology topicals, and other unique dosage systems. Our team have deep roots into the Canadian hospital space, retail pharmacy market, specialty channels, and a robust B2B platform. In addition, Juno Canada has recently embarked with product sourcing in the animal health space and remain focused on opening new delivery channels and customer groups to facilitate supply for Canadian patients. Juno is proud to supply 5 molecules deemed medically necessary by the World Health Organization on their critically essential medications list, and we are actively pursuing export opportunities to countries in need of our critical medications. To learn more about Juno Pharmaceuticals Canada please contact us at communications@junopharm.com For sales enquiries contact us at sales@junopharm.com

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

Mesentech is a clinical stage biotechnology company developing novel medicines that selectively distribute to the intended site of action. MES1022 is a clinical stage program for bone-repair being developed for 3 indications. Our preclinical pipeline includes novel compounds targeting bone-cancers.

PharmAla Biotech Inc. is a Canadian Biotechnology company dedicated to the research, development, manufacture and sales of MDMA in service to the clinical research community.

We are a Canadian publicly traded Canadian life-sciences company that provides innovation, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers quick, convenient precise and discreet™ and smoke-free choices to consumers. RDT is focused on clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries. RDT is committed to innovative solutions for future market needs — including humans, animals and plants. We are now publicly listed on the Canadian Securities Exchange: $DOSE.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem (located in France) is the recipient of multiple French scientific awards and European Union and French government grants. Sirona Biochem is a publicly-traded company. The company is listed on the TSX Venture Exchange in Canada under the symbol SBM, the OTC Pink Sheets in the United States under the symbol SRBCF and in Frankfurt under the symbol ZSB.